Previous 10 | Next 10 |
The following slide deck was published by CytomX Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: CytomX Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. CytomX Therapeutics, inc (NASDAQ: CTMX) Q3 2021 Earnings Call Nov 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: CytomX Therapeutics, inc (CTMX) Q3 2021 Earnings Call Transcript
CytomX (NASDAQ:CTMX): Q3 GAAP EPS of $0.35 beats by $0.65. Revenue of $17.59M (-1.1% Y/Y) misses by $0.79M. Press Release For further details see: CytomX EPS beats by $0.65, misses on revenue
-Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluzatamab ravtansine (CX-2009) expected in 2022- SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics,...
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody ® technology pl...
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platfor...
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platfor...
CTMX is trading at cash. They have major collaborations. The science aims to resolve a critical problem in the ADC space. For further details see: CytomX: Solving A Critical Problem In The High-Value ADC Space
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody ® technol...
The following slide deck was published by CytomX Therapeutics, Inc. in conjunction with this event. For further details see: CytomX Therapeutics (CTMX) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...